Gene analysis for cancer (neuroblastoma)
Medicare pricing data for 72 providers across 6 states
Note: These costs reflect the Medicare physician/supplier component. Hospital facility fees are billed separately and can be 2-5x the physician fee.
💡 What You Should Know
Gene analysis for cancer (neuroblastoma) (HCPCS code 81311) is a medical procedure billed to Medicare. The average Medicare-allowed cost is $289.83, but hospitals typically charge $333.65 — a 1.2x markup. Prices vary significantly by state and provider.
🏷️ Typical Out-of-Pocket Cost
Medicare patients typically pay about 20% of the allowed amount as coinsurance. Based on the average allowed cost of $289.83, your out-of-pocket cost would be approximately $57.97. Actual costs depend on your specific plan, deductible, and whether you've met your annual out-of-pocket maximum.
What Hospitals Charge vs. What Medicare Pays
Hospitals charge 1.2x more than what Medicare allows for this procedure. Medicare actually pays $289.83 on average.
Cost by State
Medicare-allowed amounts vary significantly by state
| State | Allowed Cost | Hospital Charge | Providers | Services | vs. National |
|---|---|---|---|---|---|
| Illinois | $290 | $574 | 2 | 42 | +0.0% |
| Maine | $290 | $432 | 1 | 11 | +0.0% |
| New Jersey | $290 | $376 | 4 | 73 | +0.0% |
| Pennsylvania | $290 | $296 | 2 | 27 | +0.0% |
| Florida | $290 | $332 | 25 | 14,707 | +0.0% |
| Texas | $288 | $387 | 15 | 114 | -0.6% |
⚠️ Important: These costs reflect the Medicare physician/supplier component. Hospital facility fees may be billed separately. Total out-of-pocket costs may be higher.
💊 Need post-procedure medications? Check costs on OpenPrescriber